Tetra Bio-Pharma Enters into Co-Development Agreement with MAKScientific

Tetra Bio-Pharma Inc.  a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has signed a co-development definite agreement with MAKScientific.  This agreement provides Tetra with access to novel patented new molecules with CB1 and CB2 agonist or antagonist properties.  In the long term, this agreement secures patented new drug candidates for Tetra to develop after Caumz and QIXLEEF receive marketing approval. MAKScientific is a recognized world leader in endocannabinoid research and drug development.  MAKScientific has developed a pipeline of small molecule drugs that target the cannabinoid receptors (CB1 and CB2) as well as other targets implicated in the endocannabinoid system. Under this agreement, MAKScientific will develop new molecules that will be screened by Tetra for potential efficacy in various indications including cancer, pain and inflammation as well as other potential targets of interest to Tetra.